zinnat suukaudse suspensiooni graanulid
sandoz pharmaceuticals d.d. - tsefuroksiim - suukaudse suspensiooni graanulid - 25mg 1ml 80ml 1tk; 25mg 1ml 60ml 1tk; 25mg 1ml 100ml 1tk; 25mg 1ml 50ml 1tk; 25mg 1ml 40ml 1tk
lekoklar suukaudse suspensiooni graanulid
sandoz pharmaceuticals d.d. - klaritromütsiin - suukaudse suspensiooni graanulid - 125mg 5ml 50ml 1tk; 125mg 5ml 80ml 1tk; 125mg 5ml 240ml 1tk; 125mg 5ml 120ml 1tk; 125mg 5ml 60ml 1tk
retrovir suukaudne lahus
viiv healthcare b.v. - zidovudiin - suukaudne lahus - 10mg 1ml 200ml 1tk
fintepla
ucb pharma s.a. - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptics, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
legacy® 500 sc
adama - suspensioonikontsentraat - diflufenikaan - herbitsiidid
livmarli
mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.
orfadin
swedish orphan biovitrum international ab - nitisinoon - türosineemiad - muud alimentary seedetrakti ja ainevahetust tooted, - hereditary tyrosinemia type 1 (ht 1)orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht 1) in combination with dietary restriction of tyrosine and phenylalanine. alkaptonuria (aku)orfadin is indicated for the treatment of adult patients with alkaptonuria (aku).
mirador® 250 sc
adama - suspensioonikontsentraat - asoksüstrobiin - fungitsiidid